405-85-6

Basic information

• Product Name: 4-[(3-FLUOROBENZYL)OXY]BENZENECARBOXYLIC ACID
• Synonyms: 4-[(3-FLUOROBENZYL)OXY]BENZENECARBOXYLIC ACID;4-[(3-FLUOROBENZYL)OXY]BENZOIC ACID;ASINEX-REAG BAS 13355063;TIMTEC-BB SBB010215;4-[(3-fluorophenyl)methoxy]benzoic acid
• CAS NO: 405-85-6
• Molecular Formula: C₁₄H₁₁FO₃
• Molecular Weight: 246.23
• Mol File: 405-85-6.mol
• Article Data: 4

Chemical Properties

• Melting Point: 194-196°C
• Boiling Point: 393.4°Cat760mmHg
• Flash Point: 191.7°C
• Appearance: /
• Density: 1.289g/cm³
• Vapor Pressure: 6.77E-07mmHg at 25°C
• Refractive Index: 1.589
• PKA: 4.40±0.10(Predicted)
• CAS DataBase Reference: 4-[(3-FLUOROBENZYL)OXY]BENZENECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(3-FLUOROBENZYL)OXY]BENZENECARBOXYLIC ACID(405-85-6)
• EPA Substance Registry System: 4-[(3-FLUOROBENZYL)OXY]BENZENECARBOXYLIC ACID(405-85-6)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 405-85-6(Hazardous Substances Data)

Usage

Description

4-[(3-FLUOROBENZYL)OXY]BENZENECARBOXYLIC ACID, also known as a metabolite of Safinamide, is a compound derived from the metabolism of Safinamide, a potent and selective monoamine oxidase-B (MAO-B) inhibitor. This metabolite possesses structural characteristics that allow it to interact with biological systems, potentially offering therapeutic benefits in certain medical applications.

Uses

Used in Pharmaceutical Industry:
4-[(3-FLUOROBENZYL)OXY]BENZENECARBOXYLIC ACID is used as a metabolite in the treatment of Parkinson's disease for its role in the metabolism of Safinamide. Safinamide, as an add-on treatment, helps manage the symptoms of Parkinson's disease by inhibiting the enzyme MAO-B, which is responsible for the breakdown of dopamine in the brain. This inhibition leads to an increase in dopamine levels, thereby providing relief from the motor symptoms associated with the disease.

InChI:InChI=1/C14H11FO3/c15-12-3-1-2-10(8-12)9-18-13-6-4-11(5-7-13)14(16)17/h1-8H,9H2,(H,16,17)

Upstream product

• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 99-96-7 4-hydroxy-benzoic acid 
• 454473-78-0 methyl 4-[(3-fluorobenzyl)oxy]benzoate 
• 456-42-8 m-fluorobenzyl chloride 
• 99-76-3 methyl 4-hydroxylbenzoate 

Downstream Products

• 1160250-86-1 C₁₄H₁₀ClFO₂ 

Relevant articles and documents

Discovery of benzamide-hydroxypyridinone hybrids as potent multi-targeting agents for the treatment of Alzheimer's disease

A novel class of benzamide-hydroxypyridinone (HPO) derivatives were innovatively designed, synthesised, and biologically evaluated as potential multitargeting candidates for the treatment of Alzheimer's disease (AD) through pharmacophores-merged approaches based on lead compounds 18d, benzyloxy phenyl analogs, and deferiprone (DFP). These hybrids possessed potent Monoamine oxidase B (MAO-B) inhibition as well as excellent iron chelation, with pFe3+ values ranging from 18.13 to 19.39. Among all the compounds, 8g exhibited the most potent selective MAO-B inhibitor (IC50 = 68.4 nM, SI = 213). Moreover, 8g showed favourable pharmacokinetic properties and had great potential to penetrate the BBB in silico and PAMPA-BBB assay. Molecular modelling showed that 8g could adopt an extended conformation and have more enhanced interactions with MAO-B than 18d. In vitro and in vivo assays demonstrated that 8g remarkably resisted Aβ-induced oxidation and ameliorated cognitive impairment induced by scopolamine. Taken collectively, these results suggest that compound 8g is a potential multifunctional candidate for anti-AD treatment.

Formamide pyridone iron chelating agent derivative with potential multi-target anti-AD activity as well as preparation method and application thereof

The invention provides a formamide pyridone iron chelating agent derivative shown as a formula (I) or a formula (II) which is described in the specification and a preparation method and application thereof. The formamide pyridone iron chelating agent derivative shown in the formula (I) or the formula (II) and the pharmaceutically acceptable salt thereof have the effects of inhibiting monoamine oxidase, chelating metal iron ions, resisting A beta and resisting oxidation activity. The derivative can be used for preparing medicines for resisting Alzheimer's disease, Parkinson's disease or other diseases treated by inhibiting monoamine oxidase, chelating metal iron ions, resisting A beta and resisting oxidation.